Literature DB >> 14517836

FANCD2 protein is expressed in proliferating cells of human tissues that are cancer-prone in Fanconi anaemia.

Michael Hölzel1, Paul J van Diest, Patrick Bier, Michael Wallisch, Maureen E Hoatlin, Hans Joenje, Johan P de Winter.   

Abstract

Fanconi anaemia (FA) is an inherited form of progressive pancytopenia associated with developmental defects, chromosomal instability, and cancer predisposition. At least seven distinct FA proteins function in concert to protect the genome, a key step being the activation of FANCD2 by mono-ubiquitination. This paper reports an immunohistochemical analysis of FANCD2 expression in normal human tissue. The highest expression was observed in maturing spermatocytes and fetal oocytes (consistent with a role for FANCD2 in meiosis) and in germinal centre cells of the spleen, tonsil, and lymph nodes (consistent with a role in proliferation). FANCD2 expression was also seen in tissues predisposed to cancer development in FA patients: haematopoietic cells, especially in the fetus, and squamous cell epithelia, particularly in the head and neck region and uterine cervix. FANCD2 expression was also occasionally seen in the breast and Fallopian tube epithelium, the respiratory epithelium of the trachea, and the exocrine cells of the pancreas, indicating that these tissues may also be cancer-prone in FA. FANCD2 expression is frequently expressed in proliferating cells as demonstrated by Ki-67 immunofluorescence double staining, consistent with a function of FANCD2 in DNA replication. Copyright 2003 John Wiley & Sons, Ltd.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14517836     DOI: 10.1002/path.1450

Source DB:  PubMed          Journal:  J Pathol        ISSN: 0022-3417            Impact factor:   7.996


  10 in total

1.  FANCD2 activates transcription of TAp63 and suppresses tumorigenesis.

Authors:  Eunmi Park; Hyungjin Kim; Jung Min Kim; Benjamin Primack; Sofia Vidal-Cardenas; Ye Xu; Brendan D Price; Alea A Mills; Alan D D'Andrea
Journal:  Mol Cell       Date:  2013-06-27       Impact factor: 17.970

2.  Significance of the Fanconi anemia FANCD2 protein in sporadic and metastatic human breast cancer.

Authors:  Philip S Rudland; Angela M Platt-Higgins; Lowri M Davies; Suzete de Silva Rudland; James B Wilson; Abdulaziz Aladwani; John H R Winstanley; Dong L Barraclough; Roger Barraclough; Christopher R West; Nigel J Jones
Journal:  Am J Pathol       Date:  2010-04-02       Impact factor: 4.307

3.  Heterozygote FANCD2 mutations associated with childhood T Cell ALL and testicular seminoma.

Authors:  Stephanie Smetsers; Joanne Muter; Claire Bristow; Leena Patel; Kate Chandler; Denise Bonney; Robert F Wynn; Anthony D Whetton; Andrew M Will; Davy Rockx; Hans Joenje; Gordon Strathdee; Jonathan Shanks; Eva Klopocki; Johan J P Gille; Josephine Dorsman; Stefan Meyer
Journal:  Fam Cancer       Date:  2012-12       Impact factor: 2.375

4.  Hypomorphic mutations in the gene encoding a key Fanconi anemia protein, FANCD2, sustain a significant group of FA-D2 patients with severe phenotype.

Authors:  Reinhard Kalb; Kornelia Neveling; Holger Hoehn; Hildegard Schneider; Yvonne Linka; Sat Dev Batish; Curtis Hunt; Marianne Berwick; Elsa Callen; Jordi Surralles; Jose A Casado; Juan Bueren; Angeles Dasi; Jean Soulier; Eliane Gluckman; C Michel Zwaan; Rosalina van Spaendonk; Gerard Pals; Johan P de Winter; Hans Joenje; Markus Grompe; Arleen D Auerbach; Helmut Hanenberg; Detlev Schindler
Journal:  Am J Hum Genet       Date:  2007-04-06       Impact factor: 11.025

5.  Fanconi anemia proteins are required to prevent accumulation of replication-associated DNA double-strand breaks.

Authors:  Alexandra Sobeck; Stacie Stone; Vincenzo Costanzo; Bendert de Graaf; Tanja Reuter; Johan de Winter; Michael Wallisch; Yassmine Akkari; Susan Olson; Weidong Wang; Hans Joenje; Jan L Christian; Patrick J Lupardus; Karlene A Cimprich; Jean Gautier; Maureen E Hoatlin
Journal:  Mol Cell Biol       Date:  2006-01       Impact factor: 4.272

Review 6.  The Fanconi anemia/BRCA gene network in zebrafish: embryonic expression and comparative genomics.

Authors:  Tom A Titus; Yi-Lin Yan; Catherine Wilson; Amber M Starks; Jonathan D Frohnmayer; Ruth A Bremiller; Cristian Cañestro; Adriana Rodriguez-Mari; Xinjun He; John H Postlethwait
Journal:  Mutat Res       Date:  2008-12-03       Impact factor: 2.433

7.  Loss of expression of FANCD2 protein in sporadic and hereditary breast cancer.

Authors:  Petra van der Groep; Michael Hoelzel; Horst Buerger; Hans Joenje; Johan P de Winter; Paul J van Diest
Journal:  Breast Cancer Res Treat       Date:  2007-02-27       Impact factor: 4.872

8.  Fanca deficiency reduces A/T transitions in somatic hypermutation and alters class switch recombination junctions in mouse B cells.

Authors:  Thuy Vy Nguyen; Lydia Riou; Saïd Aoufouchi; Filippo Rosselli
Journal:  J Exp Med       Date:  2014-05-05       Impact factor: 14.307

9.  Lymphopenia With Clinical and Laboratory Features of Combined Immune Deficiency in an 11-Year-Old Female With FANCD2 Variants and Fanconi Anemia.

Authors:  Roman Deniskin; Ghadir S Sasa; Sarada L Nandiwada; Nicholas L Rider
Journal:  Front Pediatr       Date:  2019-01-18       Impact factor: 3.418

10.  FANCD2 re-expression is associated with glioma grade and chemical inhibition of the Fanconi Anaemia pathway sensitises gliomas to chemotherapeutic agents.

Authors:  Abhijit A Patil; Parag Sayal; Marie-Lise Depondt; Ryan D Beveridge; Anthony Roylance; Deepti H Kriplani; Katie N Myers; Angela Cox; David Jellinek; Malee Fernando; Thomas A Carroll; Spencer J Collis
Journal:  Oncotarget       Date:  2014-08-15
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.